Prenetics Global (NASDAQ:PRE) Stock Price Up 1.8% - Still a Buy?

Key Points

• Prenetics Global's stock increased by 1.8% to a price of $7.72, with a trading volume of approximately 39,977 shares, reflecting a rise from the average daily volume.
• Wall Street analysts have maintained a consensus buy rating with an average price target of $9.00, despite the company reporting a negative EPS of ($0.80) in its latest quarterly results.
• Institutional ownership of Prenetics Global stands at 25.01%, with Nomura Holdings recently increasing its stake by 3.3%.

Prenetics Global Limited (NASDAQ:PRE - Get Free Report) rose 1.8% during trading on Tuesday . The company traded as high as $7.95 and last traded at $7.72. Approximately 39,977 shares traded hands during trading, an increase of 5% from the average daily volume of 38,229 shares. The stock had previously closed at $7.58.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded shares of Prenetics Global to a "hold" rating in a research note on Saturday, July 5th. One research analyst has rated the stock with a Buy rating, According to MarketBeat, Prenetics Global has a consensus rating of "Buy" and an average price target of $9.00.

Prenetics Global Stock Down 0.5%

The firm has a market cap of $94.11 million, a price-to-earnings ratio of -1.82 and a beta of 0.15. The stock's 50 day moving average is $8.02 and its 200 day moving average is $6.41.

Prenetics Global (NASDAQ:PRE - Get Free Report) last issued its earnings results on Thursday, June 12th. The company reported ($0.80) earnings per share for the quarter. The business had revenue of $17.31 million for the quarter. Prenetics Global had a negative return on equity of 28.07% and a negative net margin of 115.91%. Prenetics Global has set its FY 2025 guidance at EPS. Q2 2025 guidance at EPS. Analysts anticipate that Prenetics Global Limited will post -3.3 earnings per share for the current fiscal year.

Institutional Trading of Prenetics Global

A hedge fund recently bought a new stake in Prenetics Global stock. Stevens Capital Partners bought a new position in shares of Prenetics Global Limited (NASDAQ:PRE - Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 17,382 shares of the company's stock, valued at approximately $137,000. Stevens Capital Partners owned approximately 0.13% of Prenetics Global as of its most recent filing with the Securities and Exchange Commission (SEC). 25.01% of the stock is owned by institutional investors and hedge funds.

About Prenetics Global

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.